BMJ Open (Aug 2020)

Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study

  • Awtachew Berhe Woldu,
  • Abraham Aregay Desta,
  • Tewolde Wubayehu Woldearegay,
  • Kibriti Mehari Kidane,
  • Yemane Weldu Bahta,
  • Kiros Fenta Ajemu,
  • Ataklti Gebretsadik Woldegebriel,
  • Asfawosen Aregay Berhe,
  • Nega Mamo Bezabih

DOI
https://doi.org/10.1136/bmjopen-2020-038741
Journal volume & issue
Vol. 10, no. 8

Abstract

Read online

Objective This study aimed to identify determinants of immunological recovery following highly active antiretroviral therapy (HAART) among severely immunosuppressed patients at enrolment to care in Northern Ethiopia.Methods A retrospective study.Setting The study was done in Tigray Region, Northern Ethiopia.Participants The study was done among severely immunosuppressed (<200 CD4 cells/mm3) individuals at initial enrolment to care and whose samples were sent for viral load determination from April 2015 to March 2019 in Tigray Health Research Institute.Main outcomes The main outcome variable was immunological recovery, modelled using binary logistic regression.Results Among the 9687 patients with severe immunosuppression at enrolment, 2746 (28.35%, 95% CI 27.45% to 29.26%) had immunological recovery following HAART for at least 6 months. Male gender (adjusted OR (AOR)=0.50, p<0.001), age 20–34 years old (AOR=0.33, p<0.001), age ≥50 years old (AOR=0.26, p<0.001), WHO clinical stage III (OR=0.68, p=0.036) and viral non-suppression (AOR=0.38, p<0.001) were strong predictors of immunological failure.Conclusions Immunological recovery following HAART was low among severely immunosuppressed individuals at enrolment to care. Gender, age, WHO stage III and viral non-suppression were determinants of immunological recovery. Male patients, adolescents and virally non-suppressed patients should be identified as groups at higher risk for immunological failure. Therefore, greater support and intensive counselling should be prioritised among adolescents, men and virally non-suppressed patients for better immunological recovery.